Genmab — Januar 2019
-
Molecular Immunology
Volume 102, October 2018, Page 157:Potentiation of efficacy of a candidate immunotherapeutic antibody to Neisseria gonorrhoeae by enhancing IgG Fc hexamer formation. Citat: Humanized 2C7 with enhanced ability to activate complement using Hexabody
technology represents a promising adjunctive anti-gonococcal immunotherapeutic. -
-
Hej Rachel
Som mange årige Genmab investor, har jeg et spørgsmål som jeg håber du kan oplyse lidt.
Genmab mangler at flage for en forholdsvis stor milestone, som jeg formoder udløses af et salg på 2 milliarder $ af daratumumab.
Da der ikke er offentligt gjort noget endnu omkring milestonen, kan vi så forvente at betingelserne for at nå milestonen ikke er blevet opfyldt eller ?
Med Venlig Hilsen
Jan Kjær Jørgensen
-
gentogen 's
article https://sci-hub.tw/10.1016/j.molimm.2018.06.083 -
small new trial in Brazil - Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation (MAXDARA) - https://clinicaltrials.gov/ct2/show/NCT03792620?term=daratumumab+OR+ofatumumab+OR+tisotumab+OR+arzerra+OR+darzalex&lupd_s=01%2F03%2F2019&rank=2
. Ja, hvorfor nøjes med det halve 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind